These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 23659854

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K, Sundaresan A, Cheow WS.
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [Abstract] [Full Text] [Related]

  • 3. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S, Ahmad N.
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [Abstract] [Full Text] [Related]

  • 4. Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.
    Gomes CP, Gomes-da-Silva LC, Ramalho JS, de Lima MC, Simões S, Moreira JN.
    Curr Gene Ther; 2013 Jun 01; 13(3):189-201. PubMed ID: 23531193
    [Abstract] [Full Text] [Related]

  • 5. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y, Yang Z, Li Q, Song F.
    Oncology; 2008 Jun 01; 74(3-4):198-206. PubMed ID: 18714168
    [Abstract] [Full Text] [Related]

  • 6. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
    Charbe NB, Amnerkar ND, Ramesh B, Tambuwala MM, Bakshi HA, Aljabali AAA, Khadse SC, Satheeshkumar R, Satija S, Metha M, Chellappan DK, Shrivastava G, Gupta G, Negi P, Dua K, Zacconi FC.
    Acta Pharm Sin B; 2020 Nov 01; 10(11):2075-2109. PubMed ID: 33304780
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
    Sakurai Y, Hatakeyama H, Akita H, Harashima H.
    Mol Pharm; 2014 Aug 04; 11(8):2713-9. PubMed ID: 24800640
    [Abstract] [Full Text] [Related]

  • 9. [Enhancive effect of PLK1 gene silencing on sensitivity of K562/A02 cells to adriamycin].
    Liu L, Zhang M, Zou P, Tian L, Liu F.
    Ai Zheng; 2006 Apr 04; 25(4):404-8. PubMed ID: 16613670
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S, Yang XZ, Xiong MH, Sun CY, Yao YD, Zhu YH, Wang J.
    Adv Healthc Mater; 2014 Nov 04; 3(11):1792-803. PubMed ID: 24947820
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D, Chang R, Wang G, Hu B, Qiang Y, Chen Z.
    Anticancer Agents Med Chem; 2017 Nov 04; 17(7):948-954. PubMed ID: 27671301
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells].
    Han DP, Cui JT, Lu AG, Chen XH, Feng B, Zong YP, Qu S, Cao QF, Zheng MH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jan 04; 14(1):61-4. PubMed ID: 21271384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.